奥曲肽联合大剂量埃索美拉唑治疗急性非静脉曲张性上消化道出血的临床疗效分析被引量：10

导出

摘要目的：观察奥曲肽联合大剂量埃索美拉唑治疗急性非静脉曲张性上消化道出血的临床疗效。方法选择80例性非静脉曲张性上消化道出血作为研究对象，按治疗方法分为Ⅰ组（40例）和Ⅱ组（40例），Ⅰ组患者给予奥曲肽联合常规剂量埃索美拉唑，奥曲肽静脉注射0．1 mg，以50μg／h速度静脉滴注48～72 h，埃索美拉唑40 mg静脉滴注，1次／12 h。Ⅱ组患者给予奥曲肽联合大剂量埃索美拉唑，奥曲肽同Ⅰ组，埃索美拉唑首剂80 mg静脉滴注，以8 mg／h速度静脉滴注72 h，比较两组患者止血效果，观察两组患者再出血发生情况，记录止血与住院时间，测定胃内pH值，统计平均输血量及不良反应发生情况。结果Ⅱ组和Ⅰ组止血时间分别为（40．5±3．8）h和（26．2±4．0）h，差异有统计学意义（t＝3．649，P＜0．05）；Ⅱ组和Ⅰ组治疗后72 h胃内pH分别为（6．2±1．0）和（3．8±0．8），差异有统计学意义（t＝5．312，P＜0．01）；Ⅱ组和Ⅰ组平均输血量分别为（495±150）mL和（635±131）mL，差异有统计学意义，t＝3．764，P＜0．05。Ⅱ组和Ⅰ组的临床总有效率分别为90．0％和72．5％，差异有统计学意义（χ2＝6．405，P＜0．05）；Ⅱ组和Ⅰ组的再出血发生率分别为5.0％和22．5％，差异有统计学意义（χ2＝5．165，P＜0．05）；Ⅱ组和Ⅰ组的不良反应发生率分别为6．0％和5.0％，差异无统计学意义（χ2＝0．213，P＞0．05）。结论奥曲肽联合大剂量埃索美拉唑治疗急性非静脉曲张性上消化道出血的临床疗效确切，强止血效果、低再出血风险令人满意，有助于输血量的降低，且患者耐受性良好，尤其适用于大出血患者。

作者陈剑平许秉正包黎刚

机构地区东阳市人民医院急诊科

出处《中国基层医药》 CAS 2015年第7期1086-1087,共2页 Chinese Journal of Primary Medicine and Pharmacy

关键词消化道出血埃索美拉唑

分类号 R573.2 [医药卫生—消化系统]

引文网络
相关文献

参考文献8

1罗晓凤,董碧蓉.非静脉曲张性上消化道出血诊治进展[J].现代临床医学,2012,38(5):387-389. 被引量：8
2Gralnek IM, Barkun AN, BardonM. Management of acute bleeding from a peptic ulcer[ J]. N EngI J Med,2008 ,359 :928-937.
3Brzozowski T, Konture kPC, Sliwowski Z, et al. Interaction of non- steroidal anti-inflammatory drugs(NSAIDs) with Helicobacter pylo- fi in the stomach of humans and experimental animals[ J]. J Physi- ol Phamaco1,2006,57 ( Suppl 3 ) :67-79.
4Hirchowitz BL. Pepsin in the pathogenesis of pepetic unceration. In:Halter F,GamerA,Tytgat GNJ(Eds). Mechanism of peptic ul- cer healing. FalkSymposium59 [ M ]. Kluwer Academic Publishers, Dordrec ht,1999:1183-1194.
5李延青.亚太地区非静脉曲张性上消化道出血专家共识意见解读（六）：药物治疗[J].中华消化杂志,2012,32(3):149-150. 被引量：34
6Avgerinos A, Sgouros S, Viazis N, et al. Somatostatin inhibits gastri- eaeid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: a prospective, randomized, placebo-controlled trial[ J]. Seand J Gastroentero1,2005,40(5 ) :515-522.
7赵新江,徐利华,李行伟.奥曲肽联合奥美拉唑治疗消化性溃疡大出血疗效观察[J].临床医学,2014,34(4):36-37. 被引量：5
8Bosch J, Abraldes JG. Variceal bleeding: pharmacological therapy [J]. Dig Dis,2005,23( 1 ) :18-29.

二级参考文献20

1Branicki FJ, Coleman SY, Fok PJ, et al. Bleeding peptic ulcer: a pros pect i ve evaluation of risk factors for rebleeding and mortality[J]. World J Surg,1990,14(2) : 262 -270.
2Laine L, Jensen DM. Management of patients with ulcer bleeding[ J ]. Am J Gastroenterol,2012,107 ( 3 ) :345 - 360.
3Rockall TA, Logan RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage [ J ]. Gut, 1996,38 (3) :316 -321.
4Blatchford O. Murray WR. Blatchford M. A risk score to predict need for treatment for upper - gastrointestinal haemorrhage [ J ].Lancet, 2000,356 (9238) : 1318 - 1321.
5Stanley A J, Ashley D, Dalton HR, et al. Outpatient management of patients with low - risk upper - gastrointestinal haemorrhage : multicentre validation and prospective evaluation [ J ]. Lancet, 2009,373 ( 9657 ) :42 - 47.
6Lim LG, Ho KY, Chan YH, et al. Urgent endoscopy is associated with lower mortality in high - risk but hot low - risk nonvariceal upper gastrointestinal bleeding [ J ]. Endoscopy, 2011,43:300 -306.
7Barkun AN, Bardou M, Martel M, et al. Prokinetics in acute upper GI bleeding: a meta - analysis [ J ]. Gastrointest Endosc, 2010,72(6) :1138 - 1145.
8Dorward S, Sreedharan A, Leontiadis G1, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding [ J ]. Cochrane Database Syst Rev,2010, (7) :CD005415.
9Lau JY, Leung WK, Wu JCY, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding[ J]. N Engl J Med,2007,356(16) : 1631 - 1640.
10Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence -based approach based on meta- analyses of randomized controlled trims [ J ]. Clin Gastroenterol Hepatol, 2009,7 ( 1 ) : 33 - 47.